Contact: Bill Schaller
Dana-Farber Cancer Institute
Caption: Andrea Richardson, M.D., Ph.D, and her colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.
Credit: Sam Ogden
Usage Restrictions: None
Related news release: DNA marker predicts platinum drug response in breast, ovarian cancer